Literature DB >> 16449817

Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis.

Nataliya M Kushnir-Sukhov1, Erica Brittain, James C Reynolds, Cem Akin, Dean D Metcalfe.   

Abstract

BACKGROUND: Mastocytosis is associated with a pathological increase in tissue mast cells. Associated skeletal problems include a decrease in bone density and pathological fractures.
METHODS: In order to explore the relationship between bone density and the severity of mastocytosis, 21 patients with mastocytosis who underwent dual-energy X-ray absorptiometry were entered into this study. Correlation coefficients were computed between Z-scores and demographic, clinical and laboratory data. Femoral neck Z-scores correlated with serum tryptase levels when all the patients were considered (p=0.029). RESULTS AND
CONCLUSION: Patients with less severe disease had significantly lower values at the L1-L4 spine (p=0.046) and femoral neck (p=0.029) Z-scores compared to patients with more severe disease. Most patients who had low Z-scores (between -1 and -2.5) were under 50 years of age, had less severe disease and had lower serum tryptase levels. A history of gastroesophageal reflux disease and a history of hypotensive episodes correlated with lower L1-L4 spine Z-scores (p<0.05). Thus, patients with less severe disease and lower serum tryptase levels should in particular have their bone density determined with treatment appropriate to the findings. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449817     DOI: 10.1159/000091172

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

Review 1.  Endocrine manifestations of systemic mastocytosis in bone.

Authors:  Loren Wissner Greene; Kamyar Asadipooya; Patricia Freitas Corradi; Cem Akin
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

2.  Osteoporosis and osteopathy markers in patients with mastocytosis.

Authors:  Nilüfer Alpay Kanıtez; Burak Erer; Öner Doğan; Nesimi Büyükbabani; Can Baykal; Dilşad Sindel; Refik Tanakol; Akif Selim Yavuz
Journal:  Turk J Haematol       Date:  2015-03-05       Impact factor: 1.831

3.  Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome.

Authors:  Almudena Matito; José Mario Morgado; Iván Álvarez-Twose; Laura Sánchez-Muñoz; Carlos Eduardo Pedreira; María Jara-Acevedo; Cristina Teodosio; Paula Sánchez-López; Elisa Fernández-Núñez; Ricardo Moreno-Borque; Andrés García-Montero; Alberto Orfao; Luis Escribano
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

Review 4.  Hematological Diseases and Osteoporosis.

Authors:  Agostino Gaudio; Anastasia Xourafa; Rosario Rapisarda; Luca Zanoli; Salvatore Santo Signorelli; Pietro Castellino
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

5.  Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis.

Authors:  Julia Riffel; Johannes Lübke; Andreas Reiter; Philipp Riffel; Nicole Naumann; Sebastian Kreil; Georgia Metzgeroth; Alice Fabarius; Karl Sotlar; Hans-Peter Horny; Mohamad Jawhar; Daniel Overhoff; Stefan Schoenberg; Wolf-Karsten Hofmann; Thomas Henzler; Juliana Schwaab
Journal:  Sci Rep       Date:  2022-08-20       Impact factor: 4.996

Review 6.  Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management.

Authors:  Celia L Gregson; Sarah A Hardcastle; Cyrus Cooper; Jonathan H Tobias
Journal:  Rheumatology (Oxford)       Date:  2013-02-27       Impact factor: 7.580

Review 7.  The Genetic Architecture of High Bone Mass.

Authors:  Celia L Gregson; Emma L Duncan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-29       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.